Altagenics

Altagenics represents a strategic venture by GLD Partners LP to deploy transformational technologies that improve the economics and likelihood of success in drug discovery. By integrating the GigaAssay™ platform—which provides comprehensive, quantitative readouts of protein function and drug response—into a focused company structure, Altagenics aims to generate actionable datasets that rapidly translate into a differentiated pipeline. The company's scalable model is expected to yield thousands of novel, drug-like compounds targeting muscle health and degeneration, positioning it as a leader in muscle-targeted therapeutics with potential applications in sports medicine, rehabilitation, and metabolic health.

Leverages Heligenics' GigaAssay™, a next-generation functional genomics platform capable of testing hundreds of thousands of protein variants in parallel to generate deep functional datasets that map genetic variation directly to biological impact, accelerating target and drug discovery.

Altagenics faces competition from other biotechs developing therapies for muscle wasting (e.g., myostatin inhibitors, SARMs), though the market lacks approved drugs. Its main differentiation is the GigaAssay™ platform, which aims to uncover novel targets and mechanisms missed by traditional discovery methods, potentially yielding a more robust and de-risked pipeline.